共 50 条
Feedback from a European Bioanalysis Forum survey on bioanalysis of drugs in tissues
被引:1
|作者:
Mokrzycki, Nathalie
[1
]
Delrat, Pascal
[2
]
De Meulder, Marc
[3
]
Erbach, Eva
[4
]
Lentheric, Irene
[5
]
McIntosh, Morna
[6
]
Dzygiel, Pawel
[7
]
Timmerman, Philip
[3
]
机构:
[1] Labs Merck Sharp & Dohme Chibret, F-63963 Clermont Ferrand 9, France
[2] Technol SERVIER, F-45000 Orleans, France
[3] Janssen Res & Dev, B-2340 Beerse, Belgium
[4] Bayer Pharma AG Global Drug Discovery, Global Early Dev, Drug Metab & Pharmacokinet, D-13353 Berlin, Germany
[5] Harlan Labs SA, Barcelona 08130, Spain
[6] Charles River Tranent, Charles River Labs, Bioanal & Immunol, Edinburgh EH33 1NE, Midlothian, Scotland
[7] Hoffmann La Roche AG, CH-4070 Basel, Switzerland
来源:
关键词:
METHOD ESTABLISHMENT;
SUPPORT;
D O I:
10.4155/bio.14.35
中图分类号:
Q5 [生物化学];
学科分类号:
071010 ;
081704 ;
摘要:
Tissue analysis has always been a difficult discipline of bioanalysis. Laboratoriesthat perform bioanalysis in tissue are facing a lot of challenges and questions before starting experiments, from a scientific/technical point of viewregarding more regulated aspects. Actually, literature is poor regarding the more technical and scientific aspects but also beyond that no clear guidance is available on this topic and laboratories performing tissue analysis face real ambiguityregarding regulatory requirements, alwayswith the risk of under- or over-validation of the assay. For all of these reasons bioanalysis in tissue became a frequently discussed topic within the European Bioanalytical Forum (EBF) organization. The EBF then decided to treat this as a specific topic, and carried out a survey that was done in two steps between 2012 and 2013. This paper represents an exhaustive summary of the result of this survey that includes themost important aspects of tissue bioanalysis. This survey provided the team a good starting point for their discussions and resulted in an EBF recommendation paper published separately.
引用
收藏
页码:1617 / 1626
页数:10
相关论文